Revised forecast
Fiscal year ending March 2027 · Six months and full yearThe bar length represents the relative magnitude of change, based on the item that changed the most in this document.
In the domestic business, growth in the product portfolio of 鳥居薬品 and new products is expected to contribute. In the overseas business, the company expects contributions from cefiderocol and the newly acquired Radicava business, while royalty revenue is expected to benefit from income related to ViiV and the former JT pharmaceutical business. Selling, general and administrative expenses, amortization associated with M&A, and R&D expenses are expected to increase, but revenue is expected to increase by more than these costs.
Impairment losses and reversal of impairment losses (△ indicates a gain): ¥35,040 million
| Item | Details |
|---|---|
| Net Sales | Not disclosed → Cumulative second-quarter results 340,000 / Full year 700,000（Cumulative second-quarter results 59.7% / Full year 40.1%） |
| Operating profit | Not disclosed → Cumulative second-quarter results 96,000 / Full year 220,000（Cumulative second-quarter results 28.4% / Full year 32.0%） |
| Profit attributable to owners of the parent | Not disclosed → Cumulative second-quarter results 108,000 / Full year 210,000（Cumulative second-quarter results 29.3% / Full year 2.4%） |
| Net income per share | Not disclosed → Cumulative second-quarter results 126.91 / Full year 246.79 |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Six months and full year |
| Previous-period results | Revenue: ¥438,268 million; operating profit: ¥156,603 million; profit before tax: ¥200,750 million; profit for the year attributable to owners of the parent: ¥170,435 million; basic earnings per share: ¥200.36 |
| Reason for the revision | In the domestic business, growth in the product portfolio of 鳥居薬品 and new products is expected to contribute. In the overseas business, the company expects contributions from cefiderocol and the newly acquired Radicava business, while royalty revenue is expected to benefit from income related to ViiV and the former JT pharmaceutical business. Selling, general and administrative expenses, amortization associated with M&A, and R&D expenses are expected to increase, but revenue is expected to increase by more than these costs. |
| Details and amount of extraordinary loss | Impairment losses and reversal of impairment losses (△ indicates a gain): ¥35,040 million |
| Dividend forecast revision | The annual dividend forecast for the fiscal year ending March 2027 is ¥76.00 (¥38.00 at the end of the second quarter and ¥38.00 at fiscal year-end) |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In Japan, revenue growth is expected to be driven by the product portfolio of 鳥居薬品 and new products such as Quviviq and ザスベイ. Overseas, cefiderocol and the newly acquired edaravone business are expected to contribute, while royalty revenue is expected to benefit from income related to ViiV and the former JT pharmaceutical business. Expenses are also expected to increase due to the integration with 鳥居薬品, efforts to maximize the value of the Radicava business, higher amortization associated with M&A, and R&D investment in the acquired development products, but revenue is expected to increase by more than these expenses.